Program
troculeucel
Also written as “SNK01”, “SNK01 (Super Natural Killer Cells 01)” and “Study Product: SNK01”.
Its studies are mostly in Alzheimer Disease · Squamous Cell Carcinoma of Head and Neck · Neoplasms · Carcinoma, Non-Small-Cell Lung · Psoriasis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NKGen Biotech | 62 open or running | phase 2since Oct 18, 2021 | Mar 6, 2019 | Mar 2028phase 2 · NCT06189963 |
| NKMAX | 10 open or running | phase 2since Apr 21, 2021 | Apr 21, 2021 | none ahead |
Also a collaborator on its studies: affimed-gmbh.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2019First study: phase 1 study in Plaque PsoriasisNew to NKGen BiotechNKGen Biotech · NCT03894579 · 9 enrolled · Mexico
- May 3, 2019Phase 1 study in NeoplasmsNKGen Biotech · NCT03941262 · 27 enrolled · United States
- Dec 9, 2020Phase 1 study in Alzheimer DiseaseNKGen Biotech · NCT04678453 · 10 enrolled · Mexico
- Apr 21, 2021NKMAX's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to NKMAXNKMAX · NCT04872634 · 24 enrolled · Korea, Republic of
- Oct 18, 2021Phase 2 study in Squamous Cell Carcinoma of Head and NeckNKGen Biotech · NCT05099549 · 11 enrolled · United States
- Dec 6, 2023Phase 2 study in Moderate Alzheimer DiseaseNKGen Biotech · NCT06189963 · 36 planned · United States, Canada
- Nov 12, 2025Phase 2 study in Alzheimer DiseaseNKGen Biotech · NCT07228078 · 30 planned · United States
Ahead
- Mar 2028Primary completion: phase 2 study in Moderate Alzheimer DiseaseNKGen Biotech · NCT06189963
- Apr 2028Primary completion: phase 2 study in Alzheimer DiseaseNKGen Biotech · NCT07228078
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07228078Alzheimer Disease · United States | 2 | Recruiting | NKGen Biotech | Apr 2028 | 30 |
| NCT06189963Moderate Alzheimer Disease · United States, Canada | 2 | Recruiting | NKGen Biotech | Mar 2028 | 36 |
| NCT05099549Squamous Cell Carcinoma of Head and Neck · United States | 2 | Terminated | NKGen Biotech | Sep 21, 2023 | 11 |
| NCT04872634Carcinoma, Non-Small-Cell Lung · Korea, Republic of | 2 | UNKNOWN | NKMAX | May 26, 2023 | 24 |
| NCT04678453Alzheimer Disease · Mexico | 1 | Terminated | NKGen Biotech | Aug 16, 2023 | 10 |
| NCT03941262Neoplasms · United States | 1 | Completed | NKGen Biotech | Feb 17, 2023 | 27 |
| NCT03894579Plaque Psoriasis · Mexico | 1 | Completed | NKGen Biotech | Dec 3, 2019 | 9 |
How it is read
Names in the registry
- “SNK01”, 5 entries
- “SNK01 (Super Natural Killer Cells 01)”, 1 entry
- “Study Product: SNK01”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Psoriasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.